ReviewEuropean journal of medical research2025
New discoveries in therapeutic targets and drug development pathways for type 2 diabetes mellitus under the guidance of precision medicine.
Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Photobiomodulation and Low-Level Laser Therapy as Complementary Strategies in Diabetes Treatment.International journal of molecular sciences · 2026Review
- Emerging Breakthroughs in Nano-Ginseng Innovations and Their Therapeutic Implications in Type 2 Diabetes.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Association Between the Triglyceride-Glucose Index and Clinical Outcomes Modified by Diabetes Duration in Patients with Acute Coronary Syndrome and Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- PGC-1α Transcriptionally Regulated by ChREBP Mitigates Neuropathic Pain Through Promoting Microglial Fatty Acid Oxidation and Anti-Inflammatory Response.CNS neuroscience & therapeutics · 2026Article
- Overview of Cellular Therapeutics Clinical Trials: Advances, Challenges, and Future Directions.International journal of molecular sciences · 2025Review
- Research Progress of Mitochondrial Dynamics and Autophagy in Diabetic Complications: New Treatment Strategies.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Type 2 diabetes mellitus (T2DM) is a complex metabolic disease involving multiple pathophysiological mechanisms, such as insulin resistance and β-cell dysfunction. Recently, the emergence of precision medicine has ushered in new ideas and strategies for the treatment of T2DM. Studies have indicated that alterations in gut microbiota and changes in multiple micro ribonucleic acids (miRNAs) are closely associated with T2DM, suggesting that regulating miRNAs and gut microbiota may become novel therapeutic targets for T2DM. In addition, the modulation of mitophagy, regulation of glucagon-like peptide-1(GLP-1) secretion, and the application of immune cell exosomes have also demonstrated significant therapeutic potential. Furthermore, regulating inhibiting serine phosphorylation, reducing proinsulin synthesis, adjusting central nervous system function, modulating transcription factors MondoA and ChREBP, adjusting Omega-3 fatty acid levels, and regulating the mammalian target of rapamycin (mTOR) signaling pathway are also considered promising therapeutic targets. The rise of precision medicine has provided a plethora of possible targets for the treatment of T2DM, spanning a wide range of areas from epigenetic modifications to gut microbiota, immune regulation, and metabolic pathways. Future research should further explore the clinical feasibility and safety of these targeted therapies while developing personalized treatment plans to improve outcomes for T2DM patients. This article highlights the latest discoveries of molecular pharmacological targets that may play a role in the pathogenesis of T2DM over the past 5 years. In addition, from the perspective of precision medicine, this review explores potential therapeutic targets for T2DM and evaluates emerging treatment strategies and drug development pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.